Psychedelic drugs could help terminal cancer patients with existential pain, mental health, and end-of-life dread

Psilocybin-assisted therapy may improve end-of-life care for terminal cancer patients by targeting the psychological and existential suffering that conventional palliative medicine often has limited tools to address. The article describes cases and physician-led work in which terminal patients, after being assessed and supported through psychedelic sessions and post-session integration, report reduced pain-related distress, less depression and anxiety, and more ability to reconnect with meaning, relationships, and life stories. It summarizes study findings suggesting lasting mental health improvements after limited dosing, and explains barriers in the United States, where psilocybin is still tightly regulated. It also outlines the need for trained facilitation and safer screening because side effects like nausea and cardiovascular effects can occur, and some participants may not benefit or may worsen.